Medicare GLP-1 Bridge program offers Wegovy, Zepbound for $50 a month
Novo Nordisk to slash Wegovy, Ozempic list prices Board certified rheumatologist Dr. Mahsa Tehrani discusses Novo Nordisk’s decision…
Semaglutide (Wegovy) approved to treat form of liver disease
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (3 July 2026) approved a semaglutide injection (Wegovy)…
Follow safeguards to ensure your medications are safe and effective
Many people live longer and with better quality today because of the medications they take. But medications can…
Everything you need to know about GLP-1s for weight loss
Glucagon-like peptide-1 (GLP-1) receptor agonists were touted as “breakthrough” drugs in 2023 — and their popularity has soared since. …
Judge suspends Colorado’s price cap on prescription drug Embrel
DENVER — Colorado’s first attempt to cap the price of an unaffordable prescription drug has been blocked by…
Judge blocks Colorado price cap on the prescription drug Enbrel
A federal judge has temporarily blocked Colorado’s first-in-the-nation price cap on a specific prescription drug, saying that it…
Illegal weight loss drug floods SA
The man at the Johannesburg gym had an answer for every question. The injectable he was selling was…
What are statins? The uses and side effects of cholesterol medication
Your support helps us to tell the story From reproductive rights to climate change to Big Tech, The…
Pharmacist warns of heat risks for people on common medications
As hot temperatures pummel central Iowa, you may be more likely to experience heat-related side effects on certain…
Nearly 1 million bottles of heart, kidney medications recalled nationwide over ‘foreign substance’
Testing that raised concerns about possible foreign contamination has triggered a recall in the United States of nearly…
Canada approves generic version of Wegovy for weight loss
FILE – A dosage of Wegovy, March 1, 2024 in Front Royal, Va. (AP Photo/Amanda Andrade-Rhoades, File) –…
GLP-1s for Addiction: Are We There Yet?
Substance use disorders (SUDs) may become the next therapeutic target for GLP-1 receptor agonists (GLP-1s). Although the evidence…